2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
20
Myeloid
4
Other solid neoplasm
2
Dermatologic
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Recurrence
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cytarabine
905
Cyclophosphamide
899
fludarabine
525
venetoclax
489
fludarabine phosphate
468
Azacitidine
460
Rituximab
431
Methotrexate
419
Etoposide
320
Filgrastim
299
Busulfan
296
Dexamethasone
286
Vincristine
285
Daunorubicin
283
Peripheral Blood Stem Cell Transplantation
258
Whole-Body Irradiation
243
Mycophenolic Acid
232
Decitabine
230
Granulocyte Colony-Stimulating Factor
227
Tacrolimus
220
Imatinib Mesylate
211
Idarubicin
205
Melphalan
202
Cyclosporine
182
Doxorubicin
177
Radiotherapy
169
Prednisone
163
Dasatinib
163
Mitoxantrone
161
Lenalidomide
160
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
parsaclisib
×
Other hematologic neoplasm
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts